New Study Finds Aspirin Treatment Ineffective for Chronic Rhinosinusitis with Nasal Polyps
A recent clinical trial reveals that aspirin therapy offers no significant benefit for patients with chronic rhinosinusitis with nasal polyps, especially those hypersensitive to NSAIDs, emphasizing the need for alternative treatment approaches.
Recent research from the University of Eastern Finland, in collaboration with the University of Helsinki and HUS Inflammation Center, has revealed that aspirin therapy does not significantly improve symptoms or quality of life for patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in those hypersensitive to non-steroidal anti-inflammatory drugs (NSAIDs). The study was published in the journal Allergy and involves a comprehensive clinical trial involving 26 patients with NSAID-exacerbated respiratory disease (N-ERD), asthma, and severe CRSwNP.
The trial involved administering aspirin desensitization to these patients, then randomly assigning them to receive either daily aspirin or a placebo over an 11-month period. The results showed no notable difference in symptom severity, lung function, or the number of corticosteroid courses needed during flare-ups between the two groups. While some indications suggested that aspirin therapy might slightly reduce nasal polyps and improve nasal symptom-related quality of life, these effects were not statistically significant.
Furthermore, adverse effects were common, occurring in 56% of patients taking aspirin and 30% of those on placebo. Side effects ranged from worsening respiratory symptoms, increased bleeding tendencies, to abdominal discomfort. About 18% of patients in the aspirin group discontinued treatment due to side effects. The study concludes that aspirin therapy, despite being affordable, does not offer a reliable benefit for most patients with CRSwNP and hypersensitivity to NSAIDs, and identifying individuals who might benefit remains challenging.
This research highlights the importance of evidence-based treatments and suggests that current biologic medications, although effective, are often expensive. The findings aim to guide clinicians in making informed decisions about managing CRSwNP associated with NSAID hypersensitivity.
Source: https://medicalxpress.com/news/2025-09-aspirin-therapy-ineffective-chronic-rhinosinusitis.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Increasing Costs of Cardiovascular Disease Spur Focus on Young Adults' Heart Health
Recent projections highlight the rising costs of cardiovascular disease in the U.S., emphasizing the need to understand early-life social determinants to improve young adults' heart health and reduce long-term healthcare expenses.
Huntingtin Protein’s New Role in Cytoskeleton Organization Reveals Insights into Neurodegenerative Diseases
New research uncovers the role of huntingtin protein in organizing the cytoskeleton, offering fresh insights into the mechanisms of neurodegenerative diseases like Huntington's. Discover how this protein influences cell structure and neural connectivity.
Study Uncovers Attitudes of Ohio Primary Care Providers Toward Treatment of Diabetes and Opioid Use Disorder
Research reveals primary care providers in Ohio are more empathetic toward patients with opioid use disorder but are less likely to treat it themselves, highlighting stigma and organizational barriers. Expanding addiction care in primary care settings is crucial to addressing Ohio's opioid epidemic.
New Protein Target Identified for Addressing Obesity-Linked Breast Cancer
Scientists at the University of Kentucky have identified a protein called Hsp47 as a key driver of obesity-related breast cancer growth. Targeting this protein could lead to new treatments for patients with obesity-associated tumors.